Aurobindo Pharma has informed that it enclosed Press Release issued by Acrotech Biopharma LLC, a step-down wholly owned subsidiary of the Company on entering into a license agreement with Evive Biotech to commercialize Ryzneuta™ (Efbemalenograstim alfa) in the US.
The above information is a part of company’s filings submitted to BSE.